Pelareorep
- Generic Name
- Pelareorep
- Drug Type
- Biotech
- CAS Number
- 1383626-61-6
- Unique Ingredient Identifier
- S9J80L3D1U
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05519059
- Locations
- 🇨🇳
Bethune First Hospital of Jilin University, Chang chun, Jilin, China
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
- Conditions
- Prognostic Stage IV Breast Cancer AJCC v8Triple-negative Breast CancerLocally Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Mridula George, MD
- Target Recruit Count
- 25
- Registration Number
- NCT04445844
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸The Ohio State University Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, United States
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
- Conditions
- Breast Cancer Metastatic
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Oncolytics Biotech
- Target Recruit Count
- 48
- Registration Number
- NCT04215146
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 81
- Registration Number
- NCT01656538
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.